{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:57:18Z","timestamp":1790571438703,"version":"4.1.0"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0022215126105544_sec1a\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review evaluates evidence-based criteria for selecting ideal candidates for biologic therapies in chronic rhinosinusitis with nasal polyps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0022215126105544_sec2b\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative literature search of PubMed, Scopus, Embase and Web of Science (2016-2026) was performed, synthesising data from clinical trials, observational studies and European Position paper on Rhinosinusitis and Nasal Polyps\/European Forum for Research and Education in Allergy and Airway Diseasesguidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0022215126105544_sec3c\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three United States Food and Drug Administration-approved biologics (dupilumab, mepolizumab and omalizumab) effectively target severe type 2 inflammation. Ideal candidates have prior sinus surgery and greater than or equal to three criteria: elevated T2 biomarkers, systemic corticosteroid dependence, severe anosmia, impaired quality of life or comorbid asthma. Drug selection must be endotype-driven: dupilumab for broad efficacy\/non-steroidal anti-inflammatory drug exacerbated respiratory disease, mepolizumab for high eosinophilia\/eosinophilic granulomatosis with polyangiitis and omalizumab for severe allergic asthma. Therapeutic efficacy requires mandatory reassessment at six- and 12-month intervals using objective clinical thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0022215126105544_sec4d\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologics act as a targeted, complementary strategy for refractory disease. Selecting patients demands a precision medicine approach based on accurate phenotyping within a collaborative multidisciplinary framework.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s0022215126105544","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:45:44Z","timestamp":1784274344000},"page":"1-5","source":"Crossref","is-referenced-by-count":0,"title":["Navigating biologic treatments in chronic rhinosinusitis with nasal polyps: a comprehensive review of patient selection"],"prefix":"10.1017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-9289","authenticated-orcid":false,"given":"Nuray","family":"Bayar Muluk","sequence":"first","affiliation":[{"name":"K\u0131r\u0131kkale University, Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,7,17]]},"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0022215126105544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:54:34Z","timestamp":1790571274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0022215126105544\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":0,"alternative-id":["S0022215126105544"],"URL":"https:\/\/doi.org\/10.1017\/s0022215126105544","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}